{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:50Z","timestamp":1787020190973,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mulit-instiutitional CTSA Award and National Center for Research Resources and Nations Center for Advancing Translational Sciences, National Institutes of Health","award":["MCTSA005"],"award-info":[{"award-number":["MCTSA005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The purpose of this study was to examine the impact of ARC on levetiracetam concentrations during the first week following acute TBI. The hypothesis was levetiracetam concentrations are significantly lower in TBI patients with augmented renal clearance (ARC) compared to those with normal renal clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a prospective cohort pharmacokinetic study of adults with moderate to severe TBI treated with levetiracetam during the first week after injury. Serial blood collections were performed daily for analysis of levetiracetam, cystatin C, and 12-hr creatinine clearance (CrCl) determinations. Patients were divided into two cohorts: with (CrCl \u2265130\u00a0ml\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      ) and without ARC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two patients with moderate to severe TBI were included. The population consisted primarily of young male patients with severe TBI (mean age 40 years old, 68% male, median admission GCS 4). Each received levetiracetam 1000\u00a0mg IV every 12\u00a0h for the study period. ARC was present in 77.3% of patients, with significantly lower levetiracetam concentrations in ARC patients and below the conservative therapeutic range (&lt;\u20096mcg\/mL) for all study days. In patients without ARC, the serum concentrations were also below the expected range on all but two study days (Days 4 and 5). Four of the 22 (18.2%) patients exhibited seizure activity during the study period (two of these patients exhibited ARC). Cystatin C concentrations were significantly lower in patients with ARC, though the mean for all patients was within the typical normal range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ARC has a high prevalence in patients with moderate to severe TBI. Levetiracetam concentrations after standard dosing were low in all TBI patients, but significantly lower in patients with ARC. This study highlights the need to consider personalized drug dosing in TBI patients irrespective of the presence of ARC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      This study was registered at cliicaltrials.gov (NCT02437838) Registered on 08\/05\/2015,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437838\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437838<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03515-w","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T01:02:37Z","timestamp":1704157357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Enhanced renal clearance impacts levetiracetam concentrations in patients with traumatic brain injury with and without augmented renal clearance"],"prefix":"10.1186","volume":"24","author":[{"given":"Aaron M.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi Hatton","family":"Kolpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Morbitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dedrick","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise H.","family":"Rhoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"2","key":"3515_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nec.2009.10.012","volume":"21","author":"KE Wartenberg","year":"2010","unstructured":"Wartenberg KE, Mayer SA. Medical Complications after subarachnoid Hemorrhage. Neurosurg Clin N Am. 2010;21(2):325\u201338.","journal-title":"Neurosurg Clin N Am"},{"issue":"6 Suppl","key":"3515_CR2","doi-asserted-by":"publisher","first-page":"357S","DOI":"10.1378\/chest.124.6_suppl.357S","volume":"124","author":"W Geerts","year":"2003","unstructured":"Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest. 2003;124(6 Suppl):357S\u201363S.","journal-title":"Chest"},{"issue":"1","key":"3515_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0897190010388906","volume":"24","author":"SJ Martin","year":"2011","unstructured":"Martin SJ, Yost RJ. Infectious Diseases in the critically ill patients. J Pharm Pract. 2011;24(1):35\u201343.","journal-title":"J Pharm Pract"},{"issue":"1","key":"3515_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","volume":"49","author":"AA Udy","year":"2010","unstructured":"Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3515_CR5","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1186\/cc10262","volume":"15","author":"JP Baptista","year":"2011","unstructured":"Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care. 2011;15(3):R139.","journal-title":"Crit Care"},{"issue":"6","key":"3515_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1213\/ANE.0b013e3181f7107d","volume":"111","author":"A Udy","year":"2010","unstructured":"Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, et al. Augmented creatinine clearance in traumatic brain injury. Anesthesand Analg. 2010;111(6):1505\u201310.","journal-title":"Anesthesand Analg"},{"issue":"9","key":"3515_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneph.2011.92","volume":"7","author":"AA Udy","year":"2011","unstructured":"Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011;7(9):539\u201343.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"3515_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1186\/s13054-014-0657-z","volume":"18","author":"AA Udy","year":"2014","unstructured":"Udy AA, Jarrett P, Stuart J, Lassig-Smith M, Starr T, Dunlop R, et al. Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Crit Care. 2014;18(6):657.","journal-title":"Crit Care"},{"issue":"3","key":"3515_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.2231","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy. 2019;39(3):346\u201354.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"3515_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/TA.0000000000001387","volume":"82","author":"JF Barletta","year":"2017","unstructured":"Barletta JF, Mangram AJ, Byrne M, Sucher JF, Hollingworth AK, Ali-Osman FR, et al. Identifying augmented renal clearance in trauma patients: validation of the augmented renal clearance in Trauma Intensive Care scoring system. J Trauma Acute Care Surg. 2017;82(4):665\u201371.","journal-title":"J Trauma Acute Care Surg"},{"key":"3515_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12871-015-0043-7","volume":"15","author":"T Steinke","year":"2015","unstructured":"Steinke T, Moritz S, Beck S, Gnewuch C, Kees MG. Estimation of creatinine clearance using plasma creatinine or cystatin C: a secondary analysis of two pharmacokinetic studies in surgical ICU patients. BMC Anesthesiol. 2015;15:62.","journal-title":"BMC Anesthesiol"},{"issue":"6","key":"3515_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/CCM.0000000000003716","volume":"47","author":"KA Morbitzer","year":"2019","unstructured":"Morbitzer KA, Jordan JD, Dehne KA, Durr EA, Olm-Shipman CM, Rhoney DH. Enhanced renal clearance in patients with hemorrhagic Stroke. Crit Care Med. 2019;47(6):800\u20138.","journal-title":"Crit Care Med"},{"issue":"9","key":"3515_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1515\/CCLM.2005.163","volume":"43","author":"T Le Bricon","year":"2005","unstructured":"Le Bricon T, Leblanc I, Benlakehal M, Gay-Bellile C, Erlich D, Boudaoud S. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. Clin Chem Lab Med. 2005;43(9):953\u20137.","journal-title":"Clin Chem Lab Med"},{"key":"3515_CR14","doi-asserted-by":"crossref","unstructured":"Silva CM, Udy AA, Baptista JP. Urinary creatinine clearance and Pharmacokinetics studies: if we can measure it, why do we Estimate it? Antimicrob Agents Chemother. 2020;64(9).","DOI":"10.1128\/AAC.00980-20"},{"issue":"1","key":"3515_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/neu.2015.4328","volume":"34","author":"AA Udy","year":"2017","unstructured":"Udy AA, Jarrett P, Lassig-Smith M, Stuart J, Starr T, Dunlop R, et al. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. J Neurotrauma. 2017;34(1):137\u201344.","journal-title":"J Neurotrauma"},{"issue":"4","key":"3515_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/phar.1374","volume":"34","author":"AS Rowe","year":"2014","unstructured":"Rowe AS, Goodwin H, Brophy GM, Bushwitz J, Castle A, Deen D, et al. Seizure prophylaxis in neurocritical care: a review of evidence-based support. Pharmacotherapy. 2014;34(4):396\u2013409.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"3515_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1227\/NEU.0000000000001432","volume":"80","author":"N Carney","year":"2017","unstructured":"Carney N, Totten AM, O\u2019Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury. Fourth Ed Neurosurg. 2017;80(1):6\u201315.","journal-title":"Fourth Ed Neurosurg"},{"issue":"8\u20139","key":"3515_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","volume":"59","author":"M Strolin Benedetti","year":"2003","unstructured":"Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, Baltes E. Pharmacokinetics and metabolism of 14\u00a0C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 2003;59(8\u20139):621\u201330.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3515_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12028-009-9304-y","volume":"12","author":"JP Szaflarski","year":"2010","unstructured":"Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165\u201372.","journal-title":"Neurocrit Care"},{"issue":"11","key":"3515_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707\u201324.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3515_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1592\/phco.31.10.934","volume":"31","author":"DD Spencer","year":"2011","unstructured":"Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy. 2011;31(10):934\u201341.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"3515_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40262-020-00979-8","volume":"60","author":"FB Sime","year":"2021","unstructured":"Sime FB, Roberts JA, Jeffree RL, Pandey S, Adiraju S, Livermore A, et al. Population Pharmacokinetics of Levetiracetam in patients with traumatic Brain Injury and Subarachnoid Hemorrhage exhibiting augmented renal clearance. Clin Pharmacokinet. 2021;60(5):655\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"3515_CR23","doi-asserted-by":"crossref","unstructured":"Bilbao-Meseguer I, Barrasa H, Asin-Prieto E, Alarcia-Lacalle A, Rodriguez-Gascon A, Maynar J et al. Population Pharmacokinetics of Levetiracetam and Dosing evaluation in critically Ill patients with normal or augmented renal function. Pharmaceutics. 2021;13(10).","DOI":"10.3390\/pharmaceutics13101690"},{"key":"3515_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcrc.2021.04.013","volume":"64","author":"CLJ Ong","year":"2021","unstructured":"Ong CLJ, Goh PSJ, Teo MM, Lim TP, Goh KKK, Ang XY, et al. Pharmacokinetics of levetiracetam in neurosurgical ICU patients. J Crit Care. 2021;64:255\u201361.","journal-title":"J Crit Care"},{"key":"3515_CR25","doi-asserted-by":"publisher","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, Inc.; 1982.","edition":"2"},{"key":"3515_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"3515_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D DuBois","year":"1916","unstructured":"DuBois D, BuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Me. 1916;17:863\u201371.","journal-title":"Arch Intern Me"},{"issue":"4","key":"3515_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","volume":"79","author":"RW Jelliffe","year":"1973","unstructured":"Jelliffe RW, Letter. Creatinine clearance: bedside estimate. Ann Int Med. 1973;79(4):604\u20135.","journal-title":"Ann Int Med"},{"issue":"4","key":"3515_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/clpt.1981.72","volume":"29","author":"JH Hull","year":"1981","unstructured":"Hull JH, Hak LJ, Koch GG, Wargin WA, Chi SL, Mattocks AM. Influence of range of renal function and Liver Disease on predictability of creatinine clearance. Clin Pharmacol Ther. 1981;29(4):516\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"3515_CR30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/ajhp\/53.9.1028","volume":"53","author":"GA Davis","year":"1996","unstructured":"Davis GA, Chandler MH. Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm. 1996;53(9):1028\u201332.","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"3515_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3515_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3515_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.yebeh.2012.05.011","volume":"24","author":"P Klein","year":"2012","unstructured":"Klein P, Herr D, Pearl PL, Natale J, Levine Z, Nogay C, et al. Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic Epilepsy. Epilepsy Behav. 2012;24(4):457\u201361.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"3515_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12028-015-0127-8","volume":"23","author":"CC May","year":"2015","unstructured":"May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented renal clearance in patients with subarachnoid Hemorrhage. Neurocrit Care. 2015;23(3):374\u20139.","journal-title":"Neurocrit Care"},{"issue":"1","key":"3515_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1378\/chest.11-1671","volume":"142","author":"AA Udy","year":"2012","unstructured":"Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30\u20139.","journal-title":"Chest"},{"issue":"3","key":"3515_CR36","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/cc12705","volume":"17","author":"M Carlier","year":"2013","unstructured":"Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, et al. Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013;17(3):R84.","journal-title":"Crit Care"},{"issue":"3","key":"3515_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2017.11.013","volume":"51","author":"C Carrie","year":"2018","unstructured":"Carrie C, Petit L, d\u2019Houdain N, Sauvage N, Cottenceau V, Lafitte M, et al. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of beta-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents. 2018;51(3):443\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"3515_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic Drugs. Ther Drug Monit. 2003;25(3):347\u201363.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"3515_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.seizure.2014.02.003","volume":"23","author":"D Stepanova","year":"2014","unstructured":"Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure. 2014;23(5):371\u20136.","journal-title":"Seizure"},{"issue":"8","key":"3515_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJM199008233230801","volume":"323","author":"NR Temkin","year":"1990","unstructured":"Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Eng J Med. 1990;323(8):497\u2013502.","journal-title":"N Eng J Med"},{"issue":"2","key":"3515_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3171\/jns.1983.58.2.0231","volume":"58","author":"B Young","year":"1983","unstructured":"Young B, Rapp RP, Norton JA, Haack D, Tibbs PA, Bean JR. Failure of prophylactically administered phenytoin to prevent early posttraumatic seizures. J Neurosurg. 1983;58(2):231\u20135.","journal-title":"J Neurosurg"},{"issue":"6","key":"3515_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1089\/neu.2015.4131","volume":"33","author":"M Browning","year":"2016","unstructured":"Browning M, Shear DA, Bramlett HM, Dixon CE, Mondello S, Schmid KE, et al. Levetiracetam treatment in traumatic brain injury: operation brain trauma therapy. J Neurotrauma. 2016;33(6):581\u201394.","journal-title":"J Neurotrauma"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03515-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T02:04:30Z","timestamp":1712023470000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03515-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3515"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03515-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The presentation of J. Dedrick Jordan\u2019s last name has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received IRB approval from the respective institutions. (IRB #150114-University of North Carolina at Chapel Hill Institutional Review Board and the Office of Human Research Ethics; IRB#15-0343-F6A-Univeristy of Kentucky Human Research\/Institutional Review Board). and performed per the amended Declaration of Helsinki. Written informed consent, which was approved by local institutional review boards, were obtained from all study participants or legal representative as appropriate. The trial was registered \u00e0 priori in clinicaltrials.gov (NCT02437838).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}